Written Question·Department of Health and Social Care·UIN 50038
Abiraterone
Tabled: 2 May 2025
Answered: 12 May 2025
Question
Edward Morello
Liberal Democrat — West Dorset
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 29 of April 2025 to Question 46588 on Abiraterone, what discussions she has had with NICE on its engagement with health authorities on the (a) appraisal and (b) use of abi
Answer
Karin SmythThe Department has had no such discussions. Abiraterone does not have a marketing authorisation for use in the treatment of high-risk, non-metastatic prostate cancer and has not been evaluated for that indication by the National Institute for Health and C...
ⓘ
This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 50038) →